Sanofi India

Fosun's sale of Gland Pharma to become India's biggest pharma deal: Report

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon

Sanofi India posts Rs 131 cr profit in Sept quarter, revenue at Rs 692 cr

Drug firm Sanofi India on Thursday reported a net profit of Rs 131 crore for the third quarter ended September 2022. The company had posted a net profit of Rs 530 crore in the July-September quarter of last year, the company said in a regulatory filing. The drug firm follows a January-December financial year. Revenue from operations stood at Rs 692 crore in the period under review. The same stood at Rs 754 crore in the corresponding period previous year. The company said the results of the September quarter were not comparable with the same quarter last year as it had transferred its nutraceuticals business to Universal Nutriscience, enabling a gain of Rs 489 crore.

Sanofi may underperform in near term; pricing control among key risks

The decline was largely on account of divestment of its nutraceutical business and a few key brands.

Sanofi India: Strong balance sheet, high cash reserves positives for stock

Products in the price control list and growth of the non-power brand portfolio will be key monitorables

Sanofi India names Rodolfo Hrosz managing director effective June 1

He will transition from being Sanofi's GM, Consumer Healthcare business in Brazil to the new role in India as soon as regulatory approvals are in place

Sensex tanks 2,702pts, ends below 55K; Nifty gives up 16,250; Brent at $105

Closing Bell: Benchmark indices clocked their biggest one-day fall since March 2020 as Russia invaded Ukraine, rattling global markets

Stocks to Watch: Indian Hotels, TCS, Dabur, Bosch, Ashok Leyland, Insurance

Insurance related stocks could see some action as the India Protection Quotient (IPQ) survey 4, stated that term insurance ownership has gone up from 36 per cent to 43 per cent in the last two years.

Sanofi India Managing Director Rajaram Narayanan resigns

Drug firm Sanofi India on Thursday said its Managing Director Rajaram Narayanan has put in his papers

Sanofi India net profit at Rs 530 crore in September quarter

The company's revenue from operations rose to Rs 754.5 crore as compared to Rs 686.6 crore in the year-ago period

Sanofi India reports second quarter net profit at Rs 178.3 crore

Revenue from operations of the company stood at Rs 789.1 crore for the quarter under consideration

Weak Q3 show, margin pressures to keep Sanofi stock under pressure

Growth led by power brands and new launches could recover as pandemic impact wanes

Stocks to watch: Tata Consumer, GAIL, NTPC, SBI Card, Sanofi India, REC

SBI Cards and Payment Services had raised Rs 550 crore by issuing bonds on a private placement basis

Sanofi India board approves special dividend of Rs 240 per share

The company reported net profit of Rs 123 cr for the quarter ended December, 31 2020, an increase of 27% from year-ago period

Sanofi's mRNA Covid-19 vaccine candidate not ready this year, CEO says

In December last year, Sanofi had said it was targeting "earliest potential approval" of the shot in the second half of 2021, following positive preclinical data

Sanofi posts stronger-than-expected result in Q4, eyes more cost cuts

The French company, which stunned investors last year with the delay of a COVID-19 vaccine candidate, confirmed an operating income margin target of 30%

Sanofi India: Long-term investors advised to consider the stock on dips

Analysts see 19 per cent annual growth in earnings during FY20-22 with significant rise in return ratios post sale of a facility

Sanofi and GSK launch trial for protein-based coronavirus vaccine

PARIS (Reuters) - French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments

Sanofi more confident about its coronavirus vaccines, trials next month

The company is working on two of the more than 150 potential vaccines being developed across the world to tackle the Covid-19 pandemic

Sanofi India gains 5%, hits 52-week high; stock soars 8% so far in August

Early this week, the comany's parent firm Sanofi said it will acquire all of the outstanding shares of US-based Principia Biopharma Inc. for a total approximate aggregate equity value of $3.68 billion

Next target for Nifty is seen at 11,550: Vinay Rajani of HDFC Securities

Traders are advised to hold Nifty longs with 11,200 stoploss and keep it trailing as Nifty rises